Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569887568> ?p ?o ?g. }
- W2569887568 endingPage "8" @default.
- W2569887568 startingPage "1" @default.
- W2569887568 abstract "Immune checkpoint inhibitors (ICIs) targeting CTLA4 and PD1 constitute a promising class of cancer treatment but are associated with several immune-related disorders. We here review the literature reporting neurological adverse events (nAEs) associated with ICIs. A systematic search of literature, up to February 2016, mentioning nAEs in patients treated with ICIs was conducted. Eligible studies included case reports and prospective trials. One case seen in our ward was also added. Within the 59 clinical trials (totalling 9208 patients) analysed, the overall incidence of nAEs was 3.8% with anti-CTLA4 antibodies, 6.1% with anti-PD1 antibodies, and 12.0% with the combination of both. The clinical spectrum of neurological disorders was highly heterogeneous. Most of these nAEs were grade 1-2 and consisted of non-specific symptoms such as headache (55%). The incidence of high grade nAEs was below 1% for all types of treatment. Headaches, encephalopathies and meningitis were the most commonly reported (21%, 19% and 15%, respectively). Among the 27 case reports, the most common nAEs were encephalopathies, meningoradiculoneuritis, Guillain-Barré like syndromes and myasthenic syndromes. The median time of nAEs onset was 6 weeks. In most cases, drug interruption and steroids led to neurological recovery, even in conditions where steroids are not usually recommended such as Guillain-Barré syndrome." @default.
- W2569887568 created "2017-01-13" @default.
- W2569887568 creator A5005575736 @default.
- W2569887568 creator A5010282039 @default.
- W2569887568 creator A5013902226 @default.
- W2569887568 creator A5025478490 @default.
- W2569887568 creator A5041214175 @default.
- W2569887568 creator A5044994800 @default.
- W2569887568 creator A5048288225 @default.
- W2569887568 creator A5054447772 @default.
- W2569887568 creator A5082779243 @default.
- W2569887568 creator A5083589275 @default.
- W2569887568 date "2017-03-01" @default.
- W2569887568 modified "2023-10-17" @default.
- W2569887568 title "Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature" @default.
- W2569887568 cites W1556990476 @default.
- W2569887568 cites W1809627231 @default.
- W2569887568 cites W1940241680 @default.
- W2569887568 cites W1946787137 @default.
- W2569887568 cites W1965494873 @default.
- W2569887568 cites W1969965329 @default.
- W2569887568 cites W1971554504 @default.
- W2569887568 cites W1979811833 @default.
- W2569887568 cites W1979895328 @default.
- W2569887568 cites W1980628210 @default.
- W2569887568 cites W1982488143 @default.
- W2569887568 cites W1990255585 @default.
- W2569887568 cites W1990675339 @default.
- W2569887568 cites W2004372156 @default.
- W2569887568 cites W2005576578 @default.
- W2569887568 cites W2010121426 @default.
- W2569887568 cites W2031203833 @default.
- W2569887568 cites W2031529458 @default.
- W2569887568 cites W2037364960 @default.
- W2569887568 cites W2038325530 @default.
- W2569887568 cites W2040336659 @default.
- W2569887568 cites W2040851929 @default.
- W2569887568 cites W2042457667 @default.
- W2569887568 cites W2044363258 @default.
- W2569887568 cites W2057312839 @default.
- W2569887568 cites W2067948267 @default.
- W2569887568 cites W2068594961 @default.
- W2569887568 cites W2070825440 @default.
- W2569887568 cites W2095826876 @default.
- W2569887568 cites W2097995306 @default.
- W2569887568 cites W2102862705 @default.
- W2569887568 cites W2104347254 @default.
- W2569887568 cites W2105396178 @default.
- W2569887568 cites W2106511606 @default.
- W2569887568 cites W2107484016 @default.
- W2569887568 cites W2112121482 @default.
- W2569887568 cites W2114747879 @default.
- W2569887568 cites W2116548718 @default.
- W2569887568 cites W2118982164 @default.
- W2569887568 cites W2124319844 @default.
- W2569887568 cites W2125112000 @default.
- W2569887568 cites W2125616358 @default.
- W2569887568 cites W2128035403 @default.
- W2569887568 cites W2128758225 @default.
- W2569887568 cites W2129141676 @default.
- W2569887568 cites W2130723808 @default.
- W2569887568 cites W2130826590 @default.
- W2569887568 cites W2130846254 @default.
- W2569887568 cites W2134171193 @default.
- W2569887568 cites W2135707184 @default.
- W2569887568 cites W2136746908 @default.
- W2569887568 cites W2136896422 @default.
- W2569887568 cites W2137712039 @default.
- W2569887568 cites W2138134458 @default.
- W2569887568 cites W2141579931 @default.
- W2569887568 cites W2143163879 @default.
- W2569887568 cites W2143488876 @default.
- W2569887568 cites W2147622445 @default.
- W2569887568 cites W2148706732 @default.
- W2569887568 cites W2150048477 @default.
- W2569887568 cites W2152897456 @default.
- W2569887568 cites W2154391127 @default.
- W2569887568 cites W2155995527 @default.
- W2569887568 cites W2156253417 @default.
- W2569887568 cites W2156353875 @default.
- W2569887568 cites W2160834915 @default.
- W2569887568 cites W2161550811 @default.
- W2569887568 cites W2162519330 @default.
- W2569887568 cites W2164433065 @default.
- W2569887568 cites W2164918836 @default.
- W2569887568 cites W2166626276 @default.
- W2569887568 cites W2166662937 @default.
- W2569887568 cites W216902937 @default.
- W2569887568 cites W2171190137 @default.
- W2569887568 cites W2173856514 @default.
- W2569887568 cites W2194675780 @default.
- W2569887568 cites W2198093519 @default.
- W2569887568 cites W2213347440 @default.
- W2569887568 cites W2222086386 @default.
- W2569887568 cites W2265285917 @default.
- W2569887568 cites W2267594367 @default.
- W2569887568 cites W2270309512 @default.
- W2569887568 cites W2291247846 @default.